Palvella Therapeutics (PVLA) Receivables (2013 - 2024)
Palvella Therapeutics (PVLA) reported Receivables of $358000.0 for Q4 2024, down 84.61% year-over-year from $2.3 million in Q1 2024, and down 28.4% quarter-over-quarter from $500000.0 in Q3 2024.
Palvella Therapeutics (PVLA) Receivables (2013 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has 11 years of Receivables data on file, last reported at $358000.0 in Q4 2024.
- Receivables for Q4 2024 came in at $358000.0, down 84.61% year-over-year; the trailing twelve-month figure through Dec 2024 was $358000.0 (down 84.61% YoY), and the FY2024 annual result was $358000.0, down 84.61% from the prior year.
- Receivables slipped to $358000.0 in Q4 2024 per PVLA's latest filing, from $500000.0 in the prior quarter.
- Over five years, Receivables peaked at $17.0 million in Q2 2021 and troughed at $358000.0 in Q4 2024.
- A 5-year average of $5.3 million and a median of $2.6 million in 2020 frame the typical range for Receivables.
- The sharpest annual moves came in 2021 and 2022: Receivables jumped 477.45% in 2021, then plunged 95.12% in 2022.
- A 5-year view of Receivables shows it stood at $1.7 million in 2020, then soared by 94.2% to $3.3 million in 2021, then jumped by 219.38% to $10.6 million in 2022, then sank by 78.02% to $2.3 million in 2023, then sank by 84.61% to $358000.0 in 2024.
- Business Quant data shows PVLA's Receivables at $358000.0 in Q4 2024, $500000.0 in Q3 2024, and $4.5 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 358,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 4.53 Mn |
| Mar 31, 2024 | 4.91 Mn |
| Dec 31, 2023 | 2.33 Mn |
| Sep 30, 2023 | 1.05 Mn |
| Jun 30, 2023 | 952,000.00 |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 10.58 Mn |
| Sep 30, 2022 | 829,000.00 |
| Jun 30, 2022 | 1.26 Mn |
| Mar 31, 2022 | 1.64 Mn |
| Dec 31, 2021 | 3.31 Mn |
| Sep 30, 2021 | 17.00 Mn |
| Jun 30, 2021 | 17.00 Mn |
| Mar 31, 2021 | 15.81 Mn |
| Dec 31, 2020 | 1.71 Mn |
| Sep 30, 2020 | 2.94 Mn |
| Jun 30, 2020 | 10.71 Mn |
| Mar 31, 2020 | 7.27 Mn |